Roivant Is Striving Towards New Standards Of Care

Firm Has A Busy 2023 Ahead With Several Promising Data Readouts Expected

With numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.

Matt Gline headshot
• Source: Roivant

Swiss biotech Roivant Sciences’s business model could be regarded, across the biotech world, as slightly unorthodox. The firm, which focuses on developing drugs through subsidiary companies it develops called ‘vants’, has now built over 20 portfolio companies that have completed nine Phase III trials, eight of which have been successful.

Arguably, its most significant achievement to date has been the launch of its first wholly-owned product: Vtama (tapinarof) cream, 1%,...

More from Business Strategy

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.